摘要幼年特发性关节炎(juvenile idiopathic arthritis,JIA)是以关节损害为主,同时伴全身多系统累及的儿童慢性风湿病,致残率高.生物制剂改变了JIA的传统治疗模式,使JIA患者的病情明显得到改善.JIA是一种异质性疾病,2011年美国风湿病学会(ACR)发布的针对JIA的治疗建议已成为临床应用的重要参考依据.由于JIA的治疗存在一个最佳反应治疗窗,因此,生物制剂的临床应用需在明确诊断后尽早使用,而且还要注意患者在治疗过程中出现对一种生物制剂无效时,应及时换为另一种可能有效的生物制剂,尽可能达到疾病控制状态.

abstractsJuvenile idiopathic arthritis (JIA)is a type of chronic rheumatism in children. It is mainly charac-terized by joint damage,accompanied by systemic symptoms and result in significant morbidity. The application of bio-logical agents has altered the traditional treatment pattern of JIA and significantly improved the condition of JIA pa-tients. JIA is a heterogeneous disease. Treatment recommendations issued by American College of Rheumatology(ACR) in 2011 have become an important reference for JIA treatment. There is a best response window for JIA treatment. Thus, the clinic application of biological agents should be used as soon as possible after the diagnosis of JIA. Meantime,it should be noted when a preparation is invalid,it need to use another possible biological agent in time to control disease progression.